LIBRETTO-431：对于非小细胞肺癌中罕见的致癌驱动基因，是否是时候重新考虑随机的 3 期临床试验了？
LIBRETTO-431: Is it time to reconsider randomized phase 3 trials for uncommon oncogenic drivers in non-small-cell lung cancer?
机构信息
Department of Onco-Hematology, Papardo Hospital, Messina, Italy.
Department of Onco-Hematology, Papardo Hospital, Messina, Italy; Department of Human Pathology "G. Barresi", University of Messina, Messina, Italy.
出版信息
Med. 2024 Feb 9;5(2):112-114. doi: 10.1016/j.medj.2023.12.002.
PMID:38340705
Abstract
The recently published results of LIBRETTO-431 pave the way for a new standard of care in the first-line setting for RET-fusion-positive NSCLCs, which raises important clinical questions not only in the therapeutic landscape of advanced NSCLC but also in the drug development process in the era of uncommon molecular subtypes.
摘要
最近发表的 LIBRETTO-431 研究结果为 RET 融合阳性 NSCLC 一线治疗树立了新的治疗标准，这不仅对晚期 NSCLC 的治疗领域提出了重要的临床问题，也对罕见分子亚型时代的药物研发过程提出了重要的临床问题。
Zotero 插件